Business Wire

Epsilogen announces CTA approval for Phase Ib trial of MOv18 IgE in platinum-resistant ovarian cancer

Share

Epsilogen, a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, today announces that the Clinical Trial Application for the Phase Ib trial of MOv18 IgE has been approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA).

The Phase Ib study is expected to initiate later in 2024 and will evaluate the efficacy of MOv18 IgE in patients with platinum-resistant ovarian cancer (PROC).

Dr Tim Wilson, Chief Executive Officer of Epsilogen, said: “This CTA is another significant milestone for Epsilogen and the clinical development of MOv18 IgE. We look forward to progressing MOv18 IgE into a Phase Ib efficacy study later this year as we continue to demonstrate the potential of IgE antibodies as a new, differentiated class of cancer treatments.”

About MOv18 IgE

MOv18 IgE is an immunoglobulin E (IgE) antibody targeting the folate receptor alpha (FR alpha) antigen. FR alpha is present on a variety of cancers including ovarian, endometrial, lung and triple negative breast cancer. Epsilogen has successfully completed a Phase I safety study of MOv18 IgE in PROC patients. The results of the study, published in Nature Communications, found MOv18 IgE to be safe and well tolerated, with evidence of anti-tumour activity observed. Epsilogen, alongside its partner Lonza, also announced the successful completion of large-scale Good Manufacturing Practice (GMP) manufacturing of MOv18 IgE earlier this year.

About the Phase Ib study

The Phase Ib study is designed to confirm the safety and tolerability of MOv18 IgE and demonstrate efficacy in PROC. Following the dose escalation, an expansion cohort will be recruited to make a preliminary assessment of the anti-tumour activity of MOv18 IgE at a selected dose. In addition, delay to disease progression will be assessed along with a number of translational elements to generate further understanding of MOv18 IgE in the study population.

About Epsilogen Ltd

Epsilogen is a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer. IgE’s natural function is to provide immunological defence against certain parasites. This functionality makes it an ideal treatment of solid tumours due to its strong potency, enhanced tumour access and long tissue half-life.

Epsilogen’s lead product candidate, MOv18 IgE, is the first therapeutic IgE antibody to enter the clinic and encouraging data from a completed Phase I trial demonstrated MOv18 IgE to be safe and well tolerated with early signs of clinical activity. Epsilogen has recently successfully completed large scale GMP manufacture of MOv18 IgE (the first time this has been achieved for an IgE antibody) and will initiate a Phase Ib trial in platinum-resistant ovarian cancer patients later this year. The company is also developing a pipeline of IgE therapies in oncology as well as proprietary platforms including IgE bispecifics and unique IgE/IgG combination antibody molecules (IgEGs) with enhanced functionality.

Epsilogen began operations in 2017 as a spin-out of King’s College London and has attracted venture capital financing from Epidarex Capital, Novartis Venture Fund, 3B Future Health, British Patient Capital, ALSA Ventures and Schroders Capital amongst others. Find out more at epsilogen.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240707808760/en/

Contacts

Communications advisor to Epsilogen Ltd:
Simon Conway
Senior Managing Director
FTI Consulting
epsilogen@fticonsulting.com
+44 (0)20 3727 1000

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Suzano Agrees US$110 Million Purchase of Two US Industrial Facilities from Pactiv Evergreen13.7.2024 01:29:00 EEST | Press release

Suzano, the world's largest pulp producer, has announced the acquisition of industrial assets from Pactiv Evergreen in the United States. This will expand the company’s operations in North America and marks its entrance into the consumer and food service packaging segments in the region. The transaction is valued at US$110 million and includes two mills in Pine Bluff, Arkansas, and Waynesville, North Carolina, that manufacture liquid packaging board and cupstock. Subject to final regulatory approval expected later this year, these assets will add approximately 420,000 metric tonnes annually of integrated paperboard to Suzano’s production capacity. Alongside the acquisition, Suzano has signed a long-term supply deal with Pactiv Evergreen to provide liquid packaging board for its converting business. Suzano is currently the largest supplier of hardwood market pulp in North America, with US offices in Fort Lauderdale, Florida, and a research and innovation campus close to Vancouver, Canad

Oakio Set to Participate in Batimat Paris 2024 with Innovative WPC Solutions12.7.2024 16:47:00 EEST | Press release

Oakio, a pioneer in eco-friendly and high-performance wood-plastic composite (WPC) products, will be participating in the Batimat Paris 2024 exhibition. The event will be held from September 30 to October 3 at Paris Expo Porte de Versailles, offering a premier platform for showcasing the latest advancements in the construction and building materials industry. Batimat is a globally recognized event that brings together industry leaders, innovators, and professionals to explore the newest trends and technologies in construction. Oakio will be exhibiting at Booth H1-A066, where attendees can discover the full range of Oakio’s innovative products. "We are delighted to be part of Batimat 2024 and to present our comprehensive range of sustainable building solutions," said Juno Zhong, Marketing Director at Oakio. "Our products are designed to meet the growing demand for environmentally responsible and high-performance materials in both residential and commercial projects." The products showca

Nord Anglia Education and Boston College to Demonstrate the Power of Metacognition at the European Conference on Education12.7.2024 16:16:00 EEST | Press release

Dr Kate Erricker, Group Head of Education Research and Global Partnerships at Nord Anglia Education, and Dr Damian Bebell, Assistant Professor at the Lynch School of Education and Human Development, Boston College, will lead a workshop on metacognition at the European Conference on Education (ECE) on Saturday 13 July 2024. Titled “Exploring the Implementation and Outcomes of a Global Metacognition Project”, the workshop will explore how metacognition can improve learning in classrooms and showcase Nord Anglia Education’s pioneering metacognition research project involving 27 schools in 17 countries. Metacognition is being aware of and controlling one’s own learning processes. Studies have shown that metacognition can greatly enhance student learning. “Metacognition bridges the gap between knowledge and understanding,” says Dr Kate Erricker. “By teaching students to be aware of how they think and learn, we’re not just enhancing their academic performance but also preparing them for futu

BLS International Holding Anonim Şirketi (Turkey) Successfully Completes Acquisition of 100% Stake in iDATA12.7.2024 15:32:00 EEST | Press release

BLS International Services Limited, a leading global tech-enabled service partner for governments and citizens, announced the successful completion of the acquisition of 100% stake in iDATA and its wholly owned subsidiaries, through BLS International FZE (WoS of BLS) and BLS International Holding Anonim Şirketi (WoS of BLS International FZE). Turkey-based iDATA, a leading visa service provider with 37+ VACs in 15+ countries, serves Germany, Italy, and the Czech Republic. BLS acquired iDATA for ~Euro 80 Million. In 2023, iDATA reported revenues of ~Euro 27.3 Million and EBITDA of ~Euro 16 Million. This acquisition would further strengthen the overall BLS’ position as one of the leading international player in Visa and Consular services. iDATA’s existing agreements and offices will be aligned into the BLS’s network in 66 countries across the globe, enabling BLS to service more Client Governments in Europe. The transaction will be EPS (Earning per share) accretive to BLS immediately. Mr.

Oticon Medical’s Sentio™ System Receives Regulatory Clearance in the US12.7.2024 15:16:00 EEST | Press release

Oticon Medical announced today the U.S. Food and Drug Administration (FDA) clearance of its first active transcutaneous bone conduction hearing system, the Sentio System. Sentio System delivers the proven benefits of the Ponto™ System – and more – in a transcutaneous option. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240712765107/en/ The Sentio System includes an external Sentio 1 Mini sound processor and a Sentio Ti Implant placed under the skin. (Photo: Business Wire) The system includes Sentio 1 Mini, an external sound processor, and Sentio Ti Implant, placed under the skin. It is the smallest transcutaneous system available to date1. While Ponto and other percutaneous bone-anchored hearing systems use skin-protruding abutments, the Sentio System provides an alternative keeping the skin intact. The Sentio System offers an additional solution for patients and supports our commitment to "freedom of choice." “With the la

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye